Table 5 Representative reported results of treatment for NSCLC with ILD
Author | year | treatment | disease | No of all pts | combined disease | No of pts. with ILD (%) | Age | median follow-up period (month) | AE (%) | Mortality after AE (%) | 3 yr. OS (%) | 5 yr. OS (%) | %FVC (or %VC) | %DLco |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chiyo | 2003 | surgery | NSCLC | 931 | ILD | 36 (3.9) | 65.5 | 43.8 | 9 (25) | 1 (11.1) | 41.5 | 35.6 | 84.9 | ― |
Mizuno | 2012 | surgery | NSCLC | 1444 | IPF | 62 (4.3) | 71.6 | ― | 7 (13.5) | 6 (85.7) | ― | ― | %VC 95.3 | 51.1 |
Voltolini | 2013 | surgery | NSCLC | 775 | ILD | 37 (4.8) | 69.3 | 26 | 5 (13.5) | 3 (60) | ― | 52 | 91.4 | 59.7 |
Sato | 2014 | surgery | NSCLC | 41,742 | ILD | 1763 (4.2) | 71 | ― | 164 (9.3) | 72 (43.9) | ― | ― | %VC < 80% 263 | ― |
2015 | ― | 40 | %VC > 80% 1478 | ― | ||||||||||
Omori | 2015 | surgery | NSCLC | 678 | IPF | 46 | 70.9 | 34.3 | 4 (8.7) | 3 (75) | 50.9 | 22.1 | 89.8 | 70.6 |
Non-IPF | 57 | 70.9 | 1 (1.8) | 0 | 71.5 | 53.2 | 98.5 | 71.7 | ||||||
Yamaguchi | 2013 | SBRT | NSCLC, MLT | 109 | subclinical ILD | 16 (14.7) | 78 | 17.1 | 2a (12.5) | 1b (50) | 48 | ― | ― | ― |
present | 2015 | CIRT | NSCLC | 637 | ILD | 29 (4.6) | 73 | 22.8 | 2 (6.9) | 0 | 46.3 | 30.4 | 82.3 | 52.1 |
stage I NSCLC | ― | ILD | 22 | 73 | 22.6 | 2 (9.1%) | 0 | 57.2 | 42.1 | 81.8 | 55.1 |